NCT03288610

Brief Summary

The purpose of this study is to find a preoperative biomarker before cardiac surgery with cardiopulmonary bypass related to severe postoperative inflammatory response and circulatory complications. The investigators hypothesize that an increase of the preoperative stimulation of vasopressinergic system (in response to acute or chronic conditions) could lead to a microcirculatory dysfunction and favor the occurrence of vasodilatation during and after CPB and increase the symptoms of an inflammatory response after CPB. By defining a high risk population, a targeted strategy of monitoring and early or preventive treatment could improve postoperative prognosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2017

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 9, 2017

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2017

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2017

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 20, 2017

Completed
Last Updated

September 25, 2017

Status Verified

May 1, 2017

Enrollment Period

6 months

First QC Date

May 9, 2017

Last Update Submit

September 20, 2017

Conditions

Keywords

CopeptinVasopressinMicrocirculationInflammationVasodilationCardiopulmonary bypass

Outcome Measures

Primary Outcomes (1)

  • Preoperative copeptin level

    Plasmatic copeptine will be measured from routine blood sample on heparinazed tubes. The biological assay will be performed by Time-Resolved Amplified Cryptate Emission on automate Kryptor Compact plus (ThermoFisher, Clichy, France). A level above the 97° percentile of referent population will be considered pathological.

    Preoperative 24 hours

Secondary Outcomes (13)

  • Postoperative microcirculatory impairment

    Within 2h of admission in intensive care unit, before weaning of sedation and mechanical ventilation

  • Occurrence of SIRS using classical definition

    First postoperative 24 hours

  • Postoperative hemodynamical impairment

    First postoperative 24 hours

  • Perioperative copeptin kinetics

    24 hours before the operation until admission intensive care unit

  • Perioperative copeptin kinetics

    postoperative day

  • +8 more secondary outcomes

Study Arms (1)

With inflammatory response

Patients with postoperative inflammatory response as defined by the occurrence of severe SIRS and/or postoperative vasodilation syndrome. Severe SIRS is defined by meeting at least 2 SIRS criteria during 6 consecutive hours or at least 3 SIRS criterias. Classical SIRS criteria include: temperature \>38,3 or \<36°C, heart rate \>90/min, respiratory rate \>20/min or PaCO2 \<32mmHg, GB\>12000 ou \<4000 c/mm3. Postoperative vasodilation syndrome is defined by the need of continuous infusion of norepinephrine (whatever the dose) to maintain the mean arterial pressure above 60 mmHg associated to a cardiac index above or egal to 2.2 L/min/m2. Patients without postoperative severe SIRS and without postoperative vasodilation syndrome

Diagnostic Test: Preoperative copeptin level

Interventions

Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.

Also known as: Biomarker of vasopressin secretion, Systemic Inflammatory Response Syndrome (SIRS), Postoperative vasodilation syndrome, Stress response
With inflammatory response

Eligibility Criteria

Age18 Years - 81 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients hospitalized and scheduled for cardiac surgery

You may qualify if:

  • Elective surgery
  • Scheduled time of at least 24 hours
  • Cardiopulmonary bypass

You may not qualify if:

  • Urgent surgery within 24 hours of hospital admission
  • Chronic renal failure with preoperative glomerular filtration rate below 45 ml/min
  • Ongoing sepsis (ie uncontrolled endocarditis)
  • Immunosuppressive therapy (solid organ transplant recipient)
  • Previously included in this study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of critical care, Arnaud de Villeneuve Hospital

Montpellier, 34295, France

Location

Related Publications (2)

  • MacCallum NS, Finney SJ, Gordon SE, Quinlan GJ, Evans TW. Modified criteria for the systemic inflammatory response syndrome improves their utility following cardiac surgery. Chest. 2014 Jun;145(6):1197-1203. doi: 10.1378/chest.13-1023.

  • Colson PH, Bernard C, Struck J, Morgenthaler NG, Albat B, Guillon G. Post cardiac surgery vasoplegia is associated with high preoperative copeptin plasma concentration. Crit Care. 2011;15(5):R255. doi: 10.1186/cc10516. Epub 2011 Oct 25.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma: preoperative, ICU admission at POD0 and POD1 samples

MeSH Terms

Conditions

Systemic Inflammatory Response SyndromeFractures, StressDiabetes InsipidusInflammationAneurysm

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsShockFractures, BoneWounds and InjuriesKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesPituitary DiseasesEndocrine System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Philippe Gaudard, MD

    Montpellier University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 9, 2017

First Posted

September 20, 2017

Study Start

January 1, 2017

Primary Completion

July 1, 2017

Study Completion

August 1, 2017

Last Updated

September 25, 2017

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will not share

Locations